{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:55:35Z","timestamp":1788580535569,"version":"build-2803163510"},"reference-count":145,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Breast Cancer Endowed Chair","award":["EC17-02"],"award-info":[{"award-number":["EC17-02"]}]},{"name":"Love Your Sister","award":["EC17-02"],"award-info":[{"award-number":["EC17-02"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) have provided new therapeutic options and significant promise for patients with cancer, particularly where existing treatments are limited. Substantial effort in ADC development is underway globally, with 13 ADCs currently approved and many more in development. The therapeutic benefits of ADCs leverage the ability to selectively target cancer cells through antibody binding, resultant relative sparing of non-malignant tissues, and the targeted delivery of a cytotoxic payload. Consequently, this drug class has demonstrated activity in multiple malignancies refractory to standard therapeutic options. Despite this, limitations exist, including narrow therapeutic windows, unique toxicity profiles, development of therapeutic resistance, and appropriate biomarker selection. This review will describe the development of ADCs, their mechanisms of action, pivotal trials, and approved indications and identify common themes. Current challenges and opportunities will be discussed for this drug class in cancer therapeutics at a time when significant developments in antibody therapies, immunotherapy, and targeted agents are occurring.<\/jats:p>","DOI":"10.3390\/pharmaceutics15082017","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T01:50:37Z","timestamp":1690422637000},"page":"2017","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antibody\u2013Drug Conjugates: Ushering in a New Era of Cancer Therapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-5745","authenticated-orcid":false,"given":"Joshua","family":"Hurwitz","sequence":"first","affiliation":[{"name":"St. Vincent\u2019s Clinical School, Faculty of Medicine and Health, University of New South Wales, Kensington, NSW 2053, Australia"},{"name":"Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-1223","authenticated-orcid":false,"given":"Lucy Roxana","family":"Haggstrom","sequence":"additional","affiliation":[{"name":"Prince of Wales Hospital, Randwick, NSW 2031, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-8838","authenticated-orcid":false,"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s Clinical School, Faculty of Medicine and Health, University of New South Wales, Kensington, NSW 2053, Australia"},{"name":"Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000443526","article-title":"Paul Ehrlich (1854\u20131915) and His Contributions to the Foundation and Birth of Translational Medicine","volume":"8","author":"Valent","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/sj.bjc.6600309","article-title":"Anticancer Drug Development","volume":"86","author":"Loadman","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Theocharopoulos, C., Lialios, P.P., Samarkos, M., Gogas, H., and Ziogas, D.C. (2021). Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. Vaccines, 9.","DOI":"10.3390\/vaccines9101111"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2100032","DOI":"10.1002\/adfm.202100032","article-title":"Antibody-Drug-Conjugate Therapy for Hematological Cancers: Matching Cell Biology with Clinical Benefit","volume":"31","author":"Firer","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody\u2013drug conjugates: Current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/phar.1687","article-title":"Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy","volume":"36","author":"Jerjian","year":"2016","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody\u2013drug conjugates: In search of partners of choice","volume":"9","author":"Genta","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mahmood, I. (2021). Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies, 10.","DOI":"10.3390\/antib10020020"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Esapa, B., Jiang, J., Cheung, A., Chenoweth, A., Thurston, D.E., and Karagiannis, S.N. (2023). Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers, 15.","DOI":"10.3390\/cancers15061845"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues:Potential Implications as a Cancer Therapeutic Target","volume":"59","author":"Stepan","year":"2011","journal-title":"J. Histochem. Cytochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"mAbs"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cheng, J., Liang, M., Carvalho, M.F., Tigue, N., Faggioni, R., Roskos, L.K., and Vainshtein, I. (2020). Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody. Antibodies, 9.","DOI":"10.3390\/antib9030049"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2007.06883.x","article-title":"High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate","volume":"140","author":"Ingle","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: A key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1248\/cpb.c21-00258","article-title":"Recent Advances in Drug\u2013Antibody Ratio Determination of Antibody\u2013Drug Conjugates","volume":"69","author":"Matsuda","year":"2021","journal-title":"Chem. Pharm. Bull."},{"key":"ref_18","unstructured":"Wermuth, C.G., Aldous, D., Raboisson, P., and Rognan, D. (2015). The Practice of Medicinal Chemistry, Academic Press. [4th ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"687926","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2016","journal-title":"Protein Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/14728222.2013.740461","article-title":"Cathepsin B as a cancer target","volume":"17","author":"Gondi","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/bc800289a","article-title":"Novel Peptide Linkers for Highly Potent Antibody\u2212Auristatin Conjugate","volume":"19","author":"Doronina","year":"2008","journal-title":"Bioconjugate Chem."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Baah, S., Laws, M., and Rahman, K.M. (2021). Antibody\u2013drug conjugates\u2014A tutorial review. Molecules, 26.","DOI":"10.3390\/molecules26102943"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhou, Q. (2023). Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins. Molecules, 28.","DOI":"10.3390\/molecules28030917"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1002\/anie.201814215","article-title":"AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies","volume":"58","author":"Yamada","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1016\/j.xphs.2021.08.002","article-title":"Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates","volume":"110","author":"Kaempffe","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_30","first-page":"271","article-title":"Site-specific conjugation of native antibody","volume":"3","author":"Sadiki","year":"2020","journal-title":"Antib. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1021\/acs.molpharmaceut.1c00473","article-title":"Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody\u2013Drug Conjugates","volume":"18","author":"Matsuda","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121981","DOI":"10.1016\/j.jchromb.2020.121981","article-title":"Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation","volume":"1140","author":"Matsuda","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"ref_34","first-page":"728","article-title":"AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody\u2013Drug Conjugate Production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjugate Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.1021\/acs.analchem.9b02192","article-title":"Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP","volume":"91","author":"Matsuda","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jps.24338","article-title":"Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody\u2013drug conjugates","volume":"104","author":"Wiggins","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lucas, A.T., Moody, A., Schorzman, A.N., and Zamboni, W.C. (2021). Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist\u2019s Perspective. Antibodies, 10.","DOI":"10.3390\/antib10030030"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jssc.202100575","article-title":"Current approaches for the purification of antibody\u2013drug conjugates","volume":"45","author":"Matsuda","year":"2022","journal-title":"J. Sep. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2862","DOI":"10.1002\/btpr.2862","article-title":"Investigating the combination of single-pass tangential flow filtration and anion exchange chromatography for intensified mAb polishing","volume":"35","author":"Elich","year":"2019","journal-title":"Biotechnol. Prog."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1039\/C9OB01639B","article-title":"Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody\u2013drug conjugation","volume":"17","author":"Yang","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1158\/1078-0432.CCR-10-0987","article-title":"Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2\u2013Positive Breast CancerEngineered Trastuzumab-DM1 THIOMAB Drug Conjugate","volume":"16","author":"Junutula","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tumey, L.N. (2020). Antibody-Drug Conjugates: Methods and Protocols, Springer.","DOI":"10.1007\/978-1-4939-9929-3"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4161\/mabs.2.5.12645","article-title":"Recovery and purification process development for monoclonal antibody production","volume":"2","author":"Liu","year":"2010","journal-title":"mAbs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.chroma.2015.03.080","article-title":"Transient conformational modification of immunoglobulin G during purification by protein A affinity chromatography","volume":"1395","author":"Gagnon","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jcph.4","article-title":"The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model","volume":"53","author":"Zhao","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/acs.bioconjchem.7b00785","article-title":"Modulating Antibody\u2013Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification","volume":"29","author":"Su","year":"2018","journal-title":"Bioconjugate Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1039\/C6SC01831A","article-title":"Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates","volume":"8","author":"Pillow","year":"2017","journal-title":"Chem. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of Antibody-Drug Conjugates in Cancer Cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/jcph.981","article-title":"Antibody\u2013Drug Conjugates as Cancer Therapeutics: Past, Present, and Future","volume":"57","author":"Vezina","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1177\/1060028020966548","article-title":"Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer","volume":"55","author":"Seligson","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: Fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"McKertish, C.M., and Kayser, V. (2021). Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080872"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1021\/bc100480a","article-title":"Disulfide-Linked Antibody\u2212Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage","volume":"22","author":"Kellogg","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1021\/acsmedchemlett.9b00310","article-title":"Peptide-Cleavable Self-immolative Maytansinoid Antibody\u2013Drug Conjugates Designed To Provide Improved Bystander Killing","volume":"10","author":"Costoplus","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.37349\/etat.2022.00069","article-title":"New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development","volume":"3","author":"Koster","year":"2022","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dan, N., Setua, S., Kashyap, V.K., Khan, S., Jaggi, M., Yallapu, M.M., and Chauhan, S.C. (2018). Antibody-drug conjugates for cancer therapy: Chemistry to clinical implications. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020032"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jcmm.13344","article-title":"Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines","volume":"22","author":"Nettersheim","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wang, Y., Liu, L., Fan, S., Xiao, D., Xie, F., Li, W., Zhong, W., and Zhou, X. (2020). Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety. Cancers, 12.","DOI":"10.3390\/cancers12030744"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_65","first-page":"617","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Kim","year":"2023","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non\u2013Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"LBA1001","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","article-title":"Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood.V124.21.376.376","article-title":"Final Analysis of the ALFA 0701 Study","volume":"124","author":"Castaigne","year":"2014","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): Long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdv509","article-title":"Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: A systematic review and meta-analysis","volume":"27","author":"Raggi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TROP2: A potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.21037\/atm-22-5067","article-title":"Tissue factor as a new target for tumor therapy\u2014Killing two birds with one stone: A narrative review","volume":"10","author":"Li","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/ijgc-2022-003701","article-title":"Integrating antibody drug conjugates in the management of gynecologic cancers","volume":"33","author":"Mahner","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody\u2013Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Brock, K., Homer, V., Soul, G., Potter, C., Chiuzan, C., and Lee, S. (2021). Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08440-0"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/cpt.2278","article-title":"Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?","volume":"110","author":"Liao","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: A meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"834651","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 low, ultra-low, and novel complementary biomarkers: Expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: A systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014An emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","article-title":"Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates","volume":"21","author":"Erickson","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Sheyi, R., de la Torre, B.G., and Albericio, F. (2022). Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020396"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1158\/1535-7163.MCT-17-0133","article-title":"A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: Mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1) altered trafficking as mechanism of ADC resistance","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer CellsMechanisms of Resistance to Trastuzumab Emtansine (T-DM1)","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Abelman, R.O., Wu, B., Spring, L.M., Ellisen, L.W., and Bardia, A. (2023). Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers, 15.","DOI":"10.3390\/cancers15041278"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)\u2013positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody\u2013drug conjugates in solid tumors: A look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/cas.14983","article-title":"Barriers to antibody therapy in solid tumors, and their solutions","volume":"112","author":"Matsumura","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_122","first-page":"e34490","article-title":"Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review","volume":"15","author":"Sardinha","year":"2023","journal-title":"Cureus"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","article-title":"Targeting the DLL\/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development","volume":"22","author":"You","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pros.23765","article-title":"Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer","volume":"79","author":"Petrylak","year":"2019","journal-title":"Prostate"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bbrc.2012.10.123","article-title":"STEAP1 is overexpressed in cancers: A promising therapeutic target","volume":"429","author":"Moreaux","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.19.00646","article-title":"Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Danila","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","article-title":"Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas","volume":"24","author":"Thompson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2021.39.15_suppl.3015","article-title":"A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: Dose escalation results","volume":"39","author":"Tolcher","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11912-023-01367-8","article-title":"Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates","volume":"25","author":"Chu","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","article-title":"Antibody-drug conjugates and bispecific antibodies targeting cancers: Applications of click chemistry","volume":"46","author":"Hong","year":"2023","journal-title":"Arch. Pharmacal Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1055\/s-0042-1749334","article-title":"Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization","volume":"4","author":"Zong","year":"2022","journal-title":"Pharm. Front."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.29831","article-title":"A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice","volume":"138","author":"Fang","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","article-title":"Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts","volume":"14","author":"Ostermann","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: Changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","article-title":"Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor","volume":"11","author":"Wang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1038\/s41419-017-0055-y","article-title":"BCL-XL overexpression promotes tumor progression-associated properties","volume":"8","author":"Trisciuoglio","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","article-title":"Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2\/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial","volume":"4","author":"Borges","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s10147-021-01960-6","article-title":"A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma","volume":"26","author":"Tahara","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: Current landscape and future perspectives","volume":"106","author":"Giugliano","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e1565859","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_144","first-page":"A230","article-title":"378\u2005A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies","volume":"8","author":"Janku","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical Characterization and Phase I Study of an Anti\u2013HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol. Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/8\/2017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:19:08Z","timestamp":1760127548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/8\/2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":145,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["pharmaceutics15082017"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15082017","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}